摘要
目的评价急诊直接经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗ST段抬高型心肌梗死(ST-elevation myocardial infarction,STEMI)后、联合使用质子泵抑制剂(proton pump inhibitor,PPI)及氯吡格雷是否安全有效。方法回顾我院行急诊PCI术后患者,共176例,并根据联合使用PPI情况,分无PPI组(42例),PPI低暴露组(75例)及PPI高暴露组(59例),观察各组的消化道出血事件及心血管不良事件。结果平均随访时间为13±4.7月,3组总的临床不良事件无显著性差异(P>0.05)。无PPI组消化道出血事件显著增加(P<0.05);与无PPI组比较,PPI低暴露组心血管事件增加无统计学意义(P>0.05),PPI高暴露组的心血管事件显著增加(P<0.05)。结论对急诊PCI术后短期使用PPI可减少消化道出血,心血管事件增加不明显,是安全有效的。
Objective Assessment the safety and effectiveness in adhibiting clopidogrel and PPI combinedly after primary PCI. with ST-elevation myocardial infarction （STEMI）. Methods Total 176 patients underwent primary percutaneous coronary intervention（PCI） were enrolled in the study, looking into alimentary tract hemorrhage events and cardiac enents in the clopidogrel alone group （ n = 42）, low exposure group of PPI （n =75）and high exposure group of PPI（n =59）. Results Average follow-up time：13 ±4.7 months,there wash＇ t significant difference of adverse clinical events （P 〉 0.05 ）. The elopidogrel alone group had more alimentary tract hemorrhage events than the other two groups （ P 〈 0.05 ）. Compared to the elopidogrel alone group, there wasn＇ t significant difference in major adverse cardial events in low exposure group of PPI, but there was inereaseing significantly eardial events in of high exposure group （P 〈 0.05 ）. Conclusion It was safe and effective in short term usage of PPI after primary PCI, which could reduce the alimentary tract hemorrhage events,but there wasn＇t increaseing significantly in cardiac enents.
出处
《血栓与止血学》
2013年第3期103-106,共4页
Chinese Journal of Thrombosis and Hemostasis
关键词
ST段抬高型心肌梗死
经皮介入治疗
质子泵抑制剂
氯吡格雷
ST-elevation myocardial infarction
Percutaneous coronary intervention
Proton pump inhibitor
Clopidogrel
